Karen McMillin
Optometrist · Lexington, KYNPI 1942395728
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,267 of the $9,851 with a category attached, or 83.9%. 23 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 27.8% of the total. Reporting peaked in 2019 at $2,556 and has fallen 62.8% since, to $950 in 2025. Among optometrist clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 250 payments — averaging $39.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$3K
- Alcon$2K
- Sun Pharmaceutical Industries Inc.$1K
- Bausch & Lomb Americas Inc.$699
- Novartis$459
- Tarsus Pharmaceuticals, Inc.$332
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$6727%
- Travel & lodging$8629%
- Food & beverage$8,26784%
- Entertainment$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 87 | $2,736 |
| Alcon | 25 | $2,469 |
| Sun Pharmaceutical Industries Inc. | 36 | $1,054 |
| Bausch & Lomb Americas Inc. | 21 | $699 |
| Novartis | 18 | $459 |
| Tarsus Pharmaceuticals, Inc. | 10 | $332 |
| Mallinckrodt Hospital Products Inc. | 6 | $305 |
| Biotissue Holdings Inc. | 9 | $296 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $272 |
| Coopervision Inc. | 7 | $216 |
| Oyster Point Pharma, Inc. | 8 | $194 |
| Notal Vision, Inc. | 1 | $172 |
| Genentech USA, Inc. | 1 | $131 |
| Aerie Pharmaceuticals, Inc. | 1 | $111 |
| ABB Con-cise Optical Group LLC | 4 | $104 |
| AbbVie | 2 | $75 |
| Harrow Eye, LLC | 3 | $67 |
| Optos, Inc. | 1 | $50 |
| Rxsight Inc | 1 | $36 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| Dompe US, Inc. | 1 | $19 |
| Alcon Research LLC | 1 | $16 |
| Synergeyes, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES$1,098
- Acuvue$714
- Precision 1$629
- CEQUA$451
- MIEBO$324
- XIIDRA$223
- AcrySof IQ PanOptix$212
- Prokera$175
- AmnioGraft$175
- ACTHAR$138
- Precision7$136
- VABYSMO$131
- DAILIES TOTAL1$129
- TOTAL30$129
- Clariti Contact Lens$116
- INFUSE$112
- Rhopressa$111
- Rocklatan$111
- XDEMVY$109
How this compares
$9,851 in reported general payments places this provider in the 95th percentile of 712 optometrist providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 37 | $47,095 |
| XiidraLifitegrast | 34 | $45,314 |
| XdemvyLotilaner | 23 | $42,209 |
| MieboPerfluorohexyloctane/Pf | 22 | $16,801 |
| CequaCyclosporine | 14 | $12,720 |
| Latanoprost | 19 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $699 | $62,11556 claims |
| AbbVieRestasis | $75 | $47,09537 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $332 | $42,20923 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,054 | $12,72014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 712 optometrist providers in Kentucky.
Other optometrist in Lexington
- Paul KarpeckiLexington$3.6M
- Bilal AhmadLexington$150K
- Christopher KucLexington$52K
- Joe McMillinLexington$11K
- Tania PatelLexington$6K
- Danielle FrankLexington$5K
- Ashley LaneLexington$5K
- Steven SpearLexington$5K
- Howell FindleyLexington$5K
- Lisa WangLexington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.